Nivolumab for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Jul 2026: Trial registered, NCT07734116
  2. 15 Sep 2026: Trial started, NCT07734116

The trials

NCT07734116: A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
15 Sep 2026
Primary completion
30 Nov 2029
Arms
ONO-4538HSC
Results
None posted
  1. 29 Jul 2026: Trial registered
  2. 15 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant), Opdivo, Opdivo qvantig component nivolumab, Opdualag component nivolumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.